IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER (IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER).
Ionosol MB and Dextrose 5% is a solution providing electrolytes and glucose for intravenous infusion. Dextrose serves as a caloric source and may reduce protein and nitrogen losses. Electrolytes help maintain osmotic balance and acid-base equilibrium. The specific mechanism of action for the combination is supportive, providing hydration, energy, and essential ions.
| Metabolism | Dextrose is metabolized via glycolysis and subsequent pathways (e.g., Krebs cycle) primarily in the liver and other tissues. Electrolytes are utilized or excreted without significant metabolism. |
| Excretion | Dextrose is completely metabolized to CO2 and water, with negligible renal excretion. Ions (Na+, K+, Mg2+, Ca2+, Cl-, acetate, gluconate) are excreted renally in proportion to serum levels and glomerular filtration; acetate and gluconate are metabolized to bicarbonate. No biliary/fecal elimination of relevant components. |
| Half-life | Dextrose has an effective half-life of approximately 15-30 minutes for plasma clearance due to rapid cellular uptake. Ions: sodium has a half-life of minutes to hours depending on volume status; potassium ~1-1.5 hours; magnesium ~3-4 hours; calcium ~2-4 hours. Clinically, steady-state of electrolytes is achieved within 24 hours of continuous infusion. |
| Protein binding | Dextrose: negligible. Sodium: ~5% (negligible binding). Potassium: ~5%. Magnesium: ~30% (albumin). Calcium: ~45% (albumin). Chloride: negligible. Acetate/gluconate: minimal binding. |
| Volume of Distribution | Dextrose: Vd approximately equal to total body water (~0.6 L/kg). Sodium: Vd ~0.15-0.2 L/kg (extracellular fluid). Potassium: Vd ~0.4-0.5 L/kg (total body water, but primarily intracellular). Magnesium: Vd ~0.2-0.3 L/kg. Calcium: Vd ~0.1-0.15 L/kg. Clinically, these values guide loading doses; large Vd indicates extensive tissue distribution. |
| Bioavailability | Intravenous: 100%. Not administered orally or via other routes. |
| Onset of Action | Intravenous: Dextrose effect (increase blood glucose) occurs within 1-2 minutes. Electrolyte effects (e.g., serum potassium increase) begin within 5-10 minutes. |
| Duration of Action | Intravenous: Dextrose effect lasts 1-2 hours post-infusion. Electrolyte effects persist for hours depending on renal function and redistribution; potassium duration ~4-6 hours, magnesium ~6-12 hours. Continuous infusion required to maintain effects. |
Intravenous infusion; dose depends on fluid and electrolyte requirements, typically 500-1000 mL per dose, administered over 1-4 hours; frequency based on clinical need.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min) with or without dialysis due to risk of electrolyte imbalances; adjust based on serum electrolyte monitoring. |
| Liver impairment | No specific adjustments recommended for Child-Pugh class A, B, or C; monitor electrolytes and fluid balance due to risk of ascites or edema. |
| Pediatric use | Individualized based on weight (mL/kg) and clinical condition; typical maintenance: 100-120 mL/kg/day for first 10 kg, then 50 mL/kg/day for 11-20 kg, then 20 mL/kg/day for >20 kg; monitor electrolytes. |
| Geriatric use | Use with caution due to age-related renal impairment; start with lower volumes (e.g., 500 mL) and monitor fluid/electrolyte status; avoid rapid infusion to prevent volume overload. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER (IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Excreted in breast milk; M/P ratio not established. Dextrose and electrolytes are endogenous and not expected to cause adverse effects in nursing infants when administered at recommended doses. |
| Teratogenic Risk | No known teratogenic risk. Calcium and magnesium salts may cause fetal effects if levels are abnormal. Dextrose is not teratogenic. Hypersmolarity from high infusion rates may cause fetal dehydration. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hyperglycemia (severe) or diabetic ketoacidosis before correction","Hypersensitivity to any component","Severe fluid overload (e.g., pulmonary edema)","Anuria or oliguria with elevated BUN/creatinine indicating acute kidney injury"]
| Precautions | ["Monitor serum electrolytes, fluid balance, and glucose levels closely.","Risk of hyperglycemia, especially in patients with diabetes mellitus.","Risk of fluid overload in patients with heart failure, renal impairment, or edema.","Do not administer if solution is discolored or contains particulate matter.","Use with caution in patients with hepatic impairment due to altered metabolism."] |
Loading safety data…
| Monitor maternal serum electrolytes, glucose, urine output, and signs of fluid overload. Fetal heart rate monitoring during labor if infusion is used for oxytocin dilution or if electrolyte imbalances occur. |
| Fertility Effects | No known adverse effects on fertility at recommended doses. Dextrose may affect insulin secretion and ovarian function in diabetic patients. |